Research programme: kinase inhibitors - Galapagos/Teijin

Drug Profile

Research programme: kinase inhibitors - Galapagos/Teijin

Alternative Names: Kinase inhibitors research programme - BioFocus/Teijin

Latest Information Update: 13 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV; Teijin Pharma
  • Class Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 13 Apr 2007 No development reported - Preclinical for Inflammation (unspecified route)
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
  • 17 Jun 2004 Teijin has acquired global rights to develop and market anti-inflammatory drug leads from the collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top